International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer
T-REX
1 other identifier
observational
3,647
7 countries
36
Brief Summary
The T-REX study aims to clarify the actual status of metastatic lymph node (LN) distribution in colon cancer and provide reliable evidence regarding the optimal length of bowel resection and the extent of central lymph node dissection in colon cancer surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2013
Longer than P75 for all trials
36 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 30, 2013
CompletedFirst Submitted
Initial submission to the registry
October 17, 2016
CompletedFirst Posted
Study publicly available on registry
October 19, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2025
CompletedJanuary 29, 2026
January 1, 2026
10.6 years
October 17, 2016
January 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Distribution of metastatic LNs
At the time of patient registry in
Distribution of metastatic LNs
At the time of 4 years after surgery
Secondary Outcomes (2)
Prognostic outcomes according to the length of bowel resection
4 years
Prognostic outcomes according to the central radicality
4 years
Eligibility Criteria
Patients with colon cancer who will receive potentially curative surgery at participating institutions between 22 Jan 2015 and 22 Jan 2020.
You may qualify if:
- Histologically proven colon adenocarcinoma
- Pathological stage Ⅰ, Ⅱ or Ⅲ
- Potentially curative surgery
- Informed consent for observational data collection
You may not qualify if:
- Tis (mucosal cancer)
- Multiple colon cancers
- All patients with preoperative adjuvant therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (36)
University Hospital Erlangen
Erlangen, Bavaria, 91054, Germany
Aichi Cancer Centre Hospital
Nagoya, Aichi-ken, 464-8681, Japan
Fujita Health University
Toyoake, Aichi-ken, 470-1192, Japan
National Canser Centre Hospital East
Chiba, Chiba, 277-8577, Japan
Teikyo University Chiba Medical Center
Ichihara-shi, Chiba, Japan
Keiyukai Sapporo Hospital
Sapporo, Hokkaido, 003-0027, Japan
Kurume University School of Medicine
Kurume, Hukuoka-prefecture, 830-0011, Japan
Yokohama City University Medical Center
Yokohama, Kanagawa, 232-0024, Japan
Saisei-kai Yokohama-shi Nanbu Hospital
Yokohama, Kanagawa, 234-0054, Japan
Yokohama-city University
Yokohama, Kanagawa, 236-0004, Japan
Kanagawa Cancer Centre Hospital
Yokohama, Kanagawa, 241-8515, Japan
Takano Hospital
Kumamoto, Kumamoto, 862-0924, Japan
Mie University Graduate School of Medicine
Tsu, Mie-ken, 514-8507, Japan
Niigata Cancer Center Hospital
Niigata, Niigata, Japan
Osaka International Cancer Institute
Osaka, Osaka, 537-8511, Japan
Saitama Cancer Center
Kitaadachi-gun, Saitama, 362-0806, Japan
National Defense Medical College
Tokorozawa, Saitama, 359-8513, Japan
Shiga University of Medical Science
Ōtsu, Shiga, Japan
Shizuoka Cancer Centre Hospital
Sunto-gun, Shizuoka, 411-8777, Japan
Tochigi Cancer Center
Utsunomiya, Tochigi, Japan
Tokyo Medical and Dental University
Bunkyo-ku, Tokyo, 113-8519, Japan
Tokyo Metropolitan Cancer and Infectious Disease Centre Komagome Hospital
Bunkyo-ku, Tokyo, 113-8677, Japan
National Cancer Centre Central Hospital
Chuo-ku, Tokyo, 104-0045, Japan
Teikyo University School of Medicine
Itabashi-ku, Tokyo, 173-8605, Japan
Kyorin University School of Medicine
Mitaka, Tokyo, 181-8611, Japan
Tokyo Women's Medical University
Shinjuku-ku, Tokyo, 162-8666, Japan
Wakayama Medical University
Wakayama, Wakayama, Japan
Yamagata Prefectural Central Hospital
Yamagata, Yamagata, 990-2292, Japan
Klaipeda University hospital
Klaipėda, Lietuva, Lithuania
National Cancer Institute, Lithuania
Vilnius, Lithuania
I.M. Sechenov First Moscow State Medical University
Moscow, Russia
Yonsei University
Seodaemun-gu, Seoul, 03722, South Korea
University of Ulsan College of Medicine and Asan Medical Center
Songpa-Gu, Seoul, South Korea
China Medical University Hospital
Taichung, 40447, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
University of Leeds
Leeds, West Yorkshire, LS2 9JT, United Kingdom
Related Publications (1)
Shiozawa M, Ueno H, Shiomi A, Kim NK, Kim JC, Tsarkov P, Grutzmann R, Dulskas A, Liang JT, Samalavicius N, West N, Sugihara K. Study protocol for an International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer (T-REX study). Jpn J Clin Oncol. 2021 Jan 1;51(1):145-155. doi: 10.1093/jjco/hyaa115.
PMID: 33215206DERIVED
Biospecimen
* Resected surgical specimens to take photographs * Lymph nodes retrieved from Resected surgical specimens to categorise
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Kenichi Sugihara, M.D., Ph.D
Tokyo Medical and Dental University, Japan
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 17, 2016
First Posted
October 19, 2016
Study Start
May 30, 2013
Primary Completion
December 31, 2023
Study Completion
January 31, 2025
Last Updated
January 29, 2026
Record last verified: 2026-01